Research carried out in our laboratories has shown that type 1 pediatric diabetes patients, compared to controls, manifested heightened T-cell proliferative responses to HSP70. In addition, it appears that the healthy human population includes many people with measurable amounts of IgG antibodies to HSP70 and HSP60. We have validated the role of the peptides in NOD mice model. While the control groups showed 50% incidence of spontaneous diabetes emerging at approx. 13 weeks of age, significant change was observed with three of our leading peptides.
The inventors have found that PKC-derived peptides are capable of inhibiting the interaction between the PKC? enzyme and its substrate (or substrates) and to abolish or ameliorate the insulin resistance.
Cannabidiol for Type I Diabetes Treatment
Treatment of 6-12 week-old female non-obese diabetic (NOD) mice with cannabidiol (CBD) resulted in protection of 70% of the mice from diabetes and maintenance of normal glucose blood levels for 20 weeks. Plasma taken from CBD-treated mice had lower levels of both IFN? and TNF compared to plasma from diabetic-control untreated or vehicle treated mice. Histopathological examination of pancreatic islets of CBD-treated mice shows protection from destruction. Our results indicate lower incidence of diabetes following treatment with CBD in NOD mice.
